Literature DB >> 9096990

Glycemic control and prevention of retinopathy in Japanese NIDDM patients. A 10-year follow-up study.

T Nakagami1, R Kawahara, S Hori, Y Omori.   

Abstract

OBJECTIVE: To examine glycemic control for the prevention of retinopathy in early diagnosed Japanese NIDDM patients. RESEARCH DESIGN AND METHODS: There were 137 patients with NIDDM but without retinopathy who first visited our facility from 1983-1985. Their age at diagnosis ranged from 30-65 years, with a disease duration of < 3 years. The optic fundi were examined at least annually. The prevalence of retinopathy in the 10th year after registration in the study was compared in four groups stratified by mean HbA1c values for 10 years. Multiple logistic regression analysis was used to assess the relationship between retinopathy and covariates.
RESULTS: None of the patients with a mean HbA1c < 6% had retinopathy. The prevalence of retinopathy was 17.2% in the group with a mean HbA1c of 6-6.9%, 14.3% in the group with a mean HbA1c of 7-7.9%, 41.9% at a mean HbA1c of 8-8.9%, and 54.8% when the mean HbA1c exceeded 9%. The prevalence of retinopathy increased with the increase in the mean HbA1c values over 10 years (trend, P < 0.005). Multiple logistic regression analysis revealed that mean HbA1c was the only significant risk factor for the development of retinopathy.
CONCLUSIONS: Our results support the concept that an early diagnosis and better control lessen the risk for the development of retinopathy in Japanese NIDDM patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096990     DOI: 10.2337/diacare.20.4.621

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option?

Authors:  Muhammad Abdul-Ghani; Ralph DeFronzo
Journal:  Ann Transl Med       Date:  2018-12

2.  Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?

Authors:  Muhammad Abdul-Ghani; Amin Jayyous; Nidal Asaad; Sherif Helmy; Jassim Al-Suwaidi
Journal:  Ann Transl Med       Date:  2018-05

3.  Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.

Authors:  M A Abdul-Ghani; C Puckett; C Triplitt; D Maggs; J Adams; E Cersosimo; R A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2015-01-07       Impact factor: 6.577

4.  Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study.

Authors:  Maria L Ribeiro; Andras I Seres; Angela M Carneiro; Michael Stur; Alain Zourdani; Patricia Caillon; José G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

5.  Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.

Authors:  Siham Abdelgani; Curtiss Puckett; John Adams; Curtis Triplitt; Ralph A DeFronzo; Muhammad Abdul-Ghani
Journal:  Diabetes Obes Metab       Date:  2021-05-06       Impact factor: 6.408

6.  Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS.

Authors:  Yiyuan Liu; Minghui Wang; Andrew D Morris; Alex S F Doney; Graham P Leese; Ewan R Pearson; Colin N A Palmer
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

7.  Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.

Authors:  Muhammad Abdul-Ghani; Osama Migahid; Ayman Megahed; John Adams; Curtis Triplitt; Ralph A DeFronzo; Mahmoud Zirie; Amin Jayyousi
Journal:  Diabetes Care       Date:  2017-01-17       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.